Biomarkers Your Provider Should Monitor During Dual Therapy Before initiating combined TRT and GLP-1 therapy, baseline labs should include lipid panels, fasting glucose or HbA1c, liver function tests, renal function, hematocrit, and testosterone or estradiol levels as applicable
GLP-1 RAs have become cornerstone therapies for obesity and T2DM
Short S, Merkel BJ, Caffrey R, McCoy KL
The unprecedented clinical efficacy, demonstrated by universal response rates and significant weight reduction outcomes, positions this API at the forefront of pharmaceutical innovation
Under the terms of the alliance, Ascendis will carry out the early development of TransCon product candidates, funded by Novo Nordisk, with the pharma group taking over once they reach the clinical development stage.
This suggests that the progressive accumulation of lipids in the liver, which would trigger increased insulin secretion, and the accumulation of lipids in the pancreas, which would eventually lead to a reduction in -cell function, play a central pathogenetic role in the development of T2D [25]
